South Korea
· Delayed Price · Currency is KRW Aminologics Statistics
Total Valuation
Aminologics has a market cap or net worth of KRW 80.98 billion. The enterprise value is 32.76 billion.
| Market Cap | 80.98B |
| Enterprise Value | 32.76B |
Important Dates
The last earnings date was Friday, November 7, 2025.
| Earnings Date | Nov 7, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
Aminologics has 87.83 million shares outstanding. The number of shares has decreased by -23.87% in one year.
| Current Share Class | 87.83M |
| Shares Outstanding | 87.83M |
| Shares Change (YoY) | -23.87% |
| Shares Change (QoQ) | +3.19% |
| Owned by Insiders (%) | 0.64% |
| Owned by Institutions (%) | 0.17% |
| Float | 59.89M |
Valuation Ratios
The trailing PE ratio is 35.88.
| PE Ratio | 35.88 |
| Forward PE | n/a |
| PS Ratio | 4.15 |
| PB Ratio | 1.44 |
| P/TBV Ratio | 1.53 |
| P/FCF Ratio | 64.59 |
| P/OCF Ratio | 54.40 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 14.67, with an EV/FCF ratio of 26.13.
| EV / Earnings | 16.79 |
| EV / Sales | 1.68 |
| EV / EBITDA | 14.67 |
| EV / EBIT | 18.84 |
| EV / FCF | 26.13 |
Financial Position
The company has a current ratio of 2.90, with a Debt / Equity ratio of 0.24.
| Current Ratio | 2.90 |
| Quick Ratio | 2.58 |
| Debt / Equity | 0.24 |
| Debt / EBITDA | 5.91 |
| Debt / FCF | 10.53 |
| Interest Coverage | 2.29 |
Financial Efficiency
Return on equity (ROE) is 3.53% and return on invested capital (ROIC) is 1.72%.
| Return on Equity (ROE) | 3.53% |
| Return on Assets (ROA) | 1.54% |
| Return on Invested Capital (ROIC) | 1.72% |
| Return on Capital Employed (ROCE) | 3.07% |
| Revenue Per Employee | 487.91M |
| Profits Per Employee | 48.80M |
| Employee Count | 40 |
| Asset Turnover | 0.28 |
| Inventory Turnover | 1.99 |
Taxes
In the past 12 months, Aminologics has paid 359.92 million in taxes.
| Income Tax | 359.92M |
| Effective Tax Rate | 15.57% |
Stock Price Statistics
The stock price has decreased by -4.46% in the last 52 weeks. The beta is 0.61, so Aminologics's price volatility has been lower than the market average.
| Beta (5Y) | 0.61 |
| 52-Week Price Change | -4.46% |
| 50-Day Moving Average | 948.14 |
| 200-Day Moving Average | 982.02 |
| Relative Strength Index (RSI) | 45.52 |
| Average Volume (20 Days) | 757,640 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Aminologics had revenue of KRW 19.52 billion and earned 1.95 billion in profits. Earnings per share was 25.70.
| Revenue | 19.52B |
| Gross Profit | 7.61B |
| Operating Income | 1.74B |
| Pretax Income | 2.31B |
| Net Income | 1.95B |
| EBITDA | 2.23B |
| EBIT | 1.74B |
| Earnings Per Share (EPS) | 25.70 |
Balance Sheet
The company has 61.42 billion in cash and 13.20 billion in debt, giving a net cash position of 48.21 billion or 548.96 per share.
| Cash & Cash Equivalents | 61.42B |
| Total Debt | 13.20B |
| Net Cash | 48.21B |
| Net Cash Per Share | 548.96 |
| Equity (Book Value) | 56.08B |
| Book Value Per Share | 618.79 |
| Working Capital | 49.92B |
Cash Flow
In the last 12 months, operating cash flow was 1.49 billion and capital expenditures -235.00 million, giving a free cash flow of 1.25 billion.
| Operating Cash Flow | 1.49B |
| Capital Expenditures | -235.00M |
| Free Cash Flow | 1.25B |
| FCF Per Share | 14.27 |
Margins
Gross margin is 38.97%, with operating and profit margins of 8.91% and 10.00%.
| Gross Margin | 38.97% |
| Operating Margin | 8.91% |
| Pretax Margin | 11.85% |
| Profit Margin | 10.00% |
| EBITDA Margin | 11.45% |
| EBIT Margin | 8.91% |
| FCF Margin | 6.42% |
Dividends & Yields
Aminologics does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | 23.87% |
| Shareholder Yield | 23.87% |
| Earnings Yield | 2.41% |
| FCF Yield | 1.55% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Stock Splits
The last stock split was on October 23, 2009. It was a forward split with a ratio of 5.
| Last Split Date | Oct 23, 2009 |
| Split Type | Forward |
| Split Ratio | 5 |
Scores
Aminologics has an Altman Z-Score of 1.82 and a Piotroski F-Score of 4. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 1.82 |
| Piotroski F-Score | 4 |